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ARTICLE
Gut microbial co-abundance networks show
specificity in inflammatory bowel disease
and obesity
Lianmin Chen 1,2, Valerie Collij1,3,14, Martin Jaeger4,14, Inge C. L. van den Munckhof 4, Arnau Vich Vila 1,3,
Alexander Kurilshikov 1, Ranko Gacesa 1,3, Trishla Sinha 1, Marije Oosting4, Leo A. B. Joosten 4,5,
Joost H. W. Rutten4, Niels P. Riksen 4, Ramnik J. Xavier 6,7,8,9, Folkert Kuipers2,10, Cisca Wijmenga1,11,
Alexandra Zhernakova1, Mihai G. Netea 4,12,13, Rinse K. Weersma3 & Jingyuan Fu 1,2✉
The gut microbiome is an ecosystem that involves complex interactions. Currently, our
knowledge about the role of the gut microbiome in health and disease relies mainly on
differential microbial abundance, and little is known about the role of microbial interactions in
the context of human disease. Here, we construct and compare microbial co-abundance
networks using 2,379 metagenomes from four human cohorts: an inflammatory bowel dis-
ease (IBD) cohort, an obese cohort and two population-based cohorts. We find that the
strengths of 38.6% of species co-abundances and 64.3% of pathway co-abundances vary
significantly between cohorts, with 113 species and 1,050 pathway co-abundances showing
IBD-specific effects and 281 pathway co-abundances showing obesity-specific effects. We
can also replicate these IBD microbial co-abundances in longitudinal data from the IBD cohort
of the integrative human microbiome (iHMP-IBD) project. Our study identifies several key
species and pathways in IBD and obesity and provides evidence that altered microbial
abundances in disease can influence their co-abundance relationship, which expands our
current knowledge regarding microbial dysbiosis in disease.
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The human gut harbours a diverse community of micro-organisms that interact closely with both the host and eachother. Gut microorganisms are involved in digestion and
degradation of nutrients, maintenance of digestive tract integrity,
stimulation of the host immune system and modulation of the
host metabolism1–5. In recent years, associations have been
identified between gut microbiome composition and the devel-
opment of certain human diseases, including diabetes6,7, cardio-
vascular disorders8,9, obesity10,11 and chronic gastrointestinal
disorders like inflammatory bowel disease (IBD)12–14. Most
associations to human diseases have been linked to lower
microbial diversity, altered microbial composition and differing
abundances of certain microorganisms and pathways3,8,15–19.
However, the gut microbiome is an ecosystem in which microbes
can exchange or compete for nutrients, signalling molecules or
immune-evasion mechanisms through complicated ecological
interactions that are far from fully understood20–22. Enthusiasm
has thus been rising to decipher these microbial interactions in
order to detect key microbes in health and disease23,24. One way
of doing this is to create co-abundance networks based on cor-
relations, a method that has the potential to study interactions
between microbes and thereby generate hypotheses for experi-
mental validation at a later stage23,24.
Various network inference tools have been developed25–29 and
applied to infer microbial taxonomic networks in healthy indi-
viduals and in individuals with extreme longevity, gestational
diabetes, Crohn’s disease and colorectal cancer30–35. These stu-
dies have identified microbial genera that are potentially key in
health and disease, e.g. Porphyromonas and Bacteroides in
gestational diabetes33. However, these previous studies were
either based on 16S rRNA sequencing data, which yields limited
information on microbial species and pathways, or carried out in
small cohorts30–34. A further limitation of 16S sequencing is that
it can only identify microbial networks up to genus level. As
different bacterial species can have very different functional
properties, analysis at genus level cannot fully capture the bio-
chemical interactions between microbes. In consequence, the
importance of metabolic network construction from metage-
nomics data has recently been highlighted24,36,37.
Here we present a metagenomics-based network analysis for
bacterial species and metabolic pathways in 2379 individuals from 4
cohorts from the Netherlands (Supplementary Fig. 1): an IBD
cohort (n= 496), an obesity cohort (300 Obesity cohort (300OB;
n= 298), and 2 population-based cohorts (Lifelines-DEEP (LLD;
n= 1135) and 500 Functional Genomics (500FG; n= 450)). We
compare the microbial taxonomic and functional networks under
different host health conditions and identify potential key species
and pathways that shape host-associated microbial networks
(Fig. 1). We find that the microbial species and pathway co-
abundances vary significantly between cohorts and report IBD- and
obesity-specific co-abundance networks, which expand our current
knowledge regarding microbial dysbiosis in disease. The network
key species and pathways identified in IBD and obesity highlight
their potential roles in regulating the microbial ecosystem in disease.
Results
Construction of gut microbial co-abundance networks. Meta-
genomic data of the 2379 participants from the four cohorts was
processed using the same pipeline. Principle coordinate analysis
showed that microbial composition and functional profiles are largely
overlapped, although we observed a significant shift in species
composition in the IBD cohort (Supplementary Fig. 2). A total of 134
bacterial species and 343 microbial pathways that were present in
>20% of the samples in at least one cohort were included for
microbial network inference. We established microbial co-abundance
relationships by combining the SparCC29 and SpiecEasi38 methods.
For species networks, we identified 2604 co-abundances in the LLD
cohort, 1591 in the 500FG cohort, 1107 in the 300OB cohort and
2554 in the IBD cohort, yielding 3454 unique species co-abundances
in total (false discovery rate (FDR) < 0.05, Fig. 2a, Supplementary
Data 1). Notably, 82.1% of the species co-abundances also exhibited
co-occurrence (Supplementary Fig. 3, Supplementary Data 1 and 2).
For pathways, the numbers of co-abundances ranged from 37,279 in
500FG to 40,699 in LLD, yielding a total of 43,355 unique pathway
co-abundances (FDR < 0.05, Fig. 2b, Supplementary Data 3). Since
absence rate of bacterial pathways is much less than in bacterial
Metagenomic sequencing data
LLD  500FG 300OB IBD
n = 1135 n = 450 n = 298 n = 496
MetaPhlAn2 HUMAnN2
Present in >20% of samples in at least one cohort
134 species 343 pathways
Co-abundance network
(SparCC: 20× iteration and 100× permutation)
(SPIEC-EASI: glasso model)
Co-abundance network per cohort
(all co-abundances at FDR < 0.05)
Heterogeneity test across cohorts
(Cochran’s Q-test with 100× resampling)
FDR < 0.05
Differential co-abundances
Cohort-specific analysis (quantile range outlier)
(100× resampling)
(effect size in one cohort being derived from 2× interquartile range)







Specific co-abundances Key species and pathways Sub-phenotype impacts
Fig. 1 Analysis workflow of the present study. The study comprised 2,379
metagenomics samples from four cohorts: the general population LifeLines-
DEEP cohort (LLD), the 500FG cohort, an obesity cohort (300OB), and an
inflammatory bowel disease (IBD) cohort. By combining SparCC and SPIEC-
EASI methods, we constructed species and pathway co-abundance
networks in each cohort separately. The established co-abundances were
then subjected to heterogeneity testing and cohort-specificity analysis to
assess whether the effect size of each co-abundance was significantly
different between cohorts and whether the differences were driven by a
specific cohort.
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species, only 29.6% of pathway co-abundances showed co-occurrence
(Supplementary Fig. 3, Supplementary Data 3 and 4). The co-
occurrence results are summarized and further discussed in Supple-
mentary Note 1.
Microbial co-abundance strength varies between cohorts. We
hypothesized that co-abundance strengths could be different
depending on host physiological status. We thus assessed to what
extent the correlation coefficients were variable across cohorts and
characterized variable co-abundance relationships for 38.6% of the
species co-abundances and 64.3% of the pathway co-abundances
(Cochran-Q test, FDR < 0.05, Supplementary Data 1 and 3).
Differential microbial co-abundances are reflected in abun-
dance levels. When zooming in on the 100 species and 304
pathways that were involved in variable co-abundances, 76% of
these species and 84% of these pathways also showed significant
differences in their abundance levels among cohorts (analysis of
variance test FDR < 0.05, Supplementary Data 5 and 6). This
implies that the variable co-abundance relationship is largely
reflected by differential microbial abundance. We summarized
the number of differential co-abundances between species from
the same genus or from different genera (Fig. 3a). The genus with
the most heterogeneous co-abundances was Streptococcus, and a
large number of variable co-abundances were observed not only
between different Streptococcus species but also between Strep-
tococcus species and species from other genera such as Eubac-
terium and Veillonella (Fig. 3a). In particular, Streptococcus
species were higher in the IBD cohort, consistent with the results
of previous studies14,39. A similar observation was found for the
pathway co-abundances, particularly for amino acid biosynthesis
pathways, which showed variability not only within themselves
but also with respect to various pathways related to nucleoside
and nucleotide biosynthesis (Fig. 3b).
Specific microbial co-abundances are enriched in disease
cohorts. Next, we analysed whether the variable co-abundance
relationships were driven by a particular cohort, i.e. whether the co-
abundance strength in one cohort was very different from those in
the other three cohorts. After correcting for the age and sex differ-
ences between cohorts, 120 species co-abundances (Supplementary
Fig. 4) and 1448 pathway co-abundances (Supplementary Fig. 5) still
showed cohort specificity with an FDR of 7.6%, as estimated by
permutation (Supplementary Data 1 and 3). Interestingly, cohort-
specific co-abundances were significantly enriched in the disease
cohorts compared to the population-based cohorts: 113 (94%) species
co-abundances and 1050 (72%) pathway co-abundances were spe-
cifically related to the IBD cohort (Fisher’s test P= 1.2 × 10−56 and
P < 10−260, respectively, Fig. 3c, d) and 281 (19.4%) pathway co-
abundances were specifically related to the 300OB cohort (Fisher’s
test P= 2.9 × 10−29), as compared to only 3 species and 117 pathway
co-abundance relationships specific to the population-based cohorts
LLD and 500FG (Fig. 3c, d). Our results highlight that microbial co-
abundances are dependent on host health and disease status. Below
we discuss the microbial co-abundance networks in IBD and 300OB
in more detail, further replicate our findings in independent cohorts
and assess the relevance of disease subtypes, disease characteristics
and medication usage.
The microbial co-abundance network in IBD. Replication of the
IBD network in the integrative Human Microbiome Project
(iHMP-IBD) cohort: Of the 2554 species and 37,699 pathway co-
abundances established in our IBD cohort, we were able to assess
2090 species co-abundances and 37,106 pathway co-abundances
in 77 IBD individuals from the iHMP-IBD39. In the baseline
samples of the iHMP-IBD cohort, 531 species co-abundances
(25.4%) and 21,882 (59.0%) pathway co-abundance could be
replicated at P < 0.05 (Supplementary Data 7 and 8)39. The
relatively low replication rate in species co-abundances is largely a
power issue, as we also observed that 1705 (81.6%) species co-
abundances and 24,165 (65.1%) pathway co-abundances showed
no significant difference in their co-abundance strengths between
our IBD cohort and the iHMP-IBD cohort (Cochran-Q test, P >
0.05, Supplementary Fig. 6, Supplementary Data 7 and 8). We
then compared the IBD networks between the first and last time
points of the iHMP-IBD cohort (~1 year apart) and replicated
90.6% of species co-abundances and 99.6% of pathway co-
abundances (Cochran-Q test, P > 0.05, Supplementary Fig. 6,
Supplementary Data 7 and 8). This suggests that our estimation
of co-abundance strengths in IBD was largely replicable in a
different cohort and was stable across time.
Microbial networks of IBD in relation to disease characteristics:
Previous studies have shown that observed microbial abundance
differences could be explained by certain disease characteristics of
IBD14. We therefore hypothesized that this could also be the case for
co-abundance relationships. We assessed whether IBD co-abundances
(including IBD co-abundances at FDR< 0.05 and IBD-specific co-
abundances) could be related to the disease subtypes [ulcerative
colitis (UC, n= 189) vs. Crohn’s disease (CD, n= 276)], disease

















































Fig. 2 Microbial co-abundance networks in each cohort. a Venn diagram of the numbers of species co-abundances detected in each cohort. In total, we
identified 3454 co-abundance relationships significant at FDR < 0.05 in at least one cohort by combing SparCC and SpiecEasi. b Venn diagram of the
numbers of species co-abundances detected in each cohort. Similarly, at the microbial metabolic pathway level, 43,355 co-abundance relationships were
detected at FDR < 0.05 in at least one cohort by combing SparCC and SpiecEasi.
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[inflammation (n= 121) vs. no inflammation (n= 377)] (Supple-
mentary Table 1). Most of the co-abundance relationships were
comparable between disease characteristics, and only a few showed
significant differences at FDR< 0.05 (Supplementary Fig. 7, Supple-
mentary Data 9 and 10), namely 16 species co-abundances related to
disease subtypes and 8 species co-abundances related to location. For
the pathway co-abundances, 91 were related to disease subtypes, 24 to
location and 3 to activity (Cochran-Q test FDR < 0.05, Supplementary
Fig. 7). Out of these, five co-abundance relationships were related to
an important butyrate producer, Faecalibacterium prausnitzii, which
showed stronger co-abundance relationships in UC compared to CD.
One example here was the negative co-abundance relationship of F.
prausnitzii with Haemophilus parainfluenzae, a species known to
have pathogenic properties40.
Microbial networks of IBD in relation to medication: We further
tested whether drug usage can affect microbial co-abundance, as
usage of antibiotics (20.0%) and proton pump inhibitors (PPIs;
26.5%) was higher in patients with IBD than in the general
population cohorts (1.1% and 8.4%) (Supplementary Table 1). Here
we detected no significant difference in species co-abundances
between antibiotic users and non-users (Cochran-Q test FDR >
0.05, Supplementary Fig. 7), while 1049 out of 37,959 (3.7%)
pathway co-abundance relationships showed statistically significant
differences between PPI users and non-users, in particular related to
the isoprene biosynthesis and methylerythritol phosphate pathways
(Cochran-Q test FDR < 0.05, Supplementary Fig. 7, Supplementary
Data 10).
Key species and pathways in IBD: When comparing microbial
co-abundance in IBD to the other 3 cohorts, we identified
113 species co-abundances and 1050 pathway co-abundances that
showed significantly different effects compared to the other 3
cohorts. We then assessed whether these IBD-specific co-
abundances were highly connected to a specific pathway or
species that may be disease relevant24, and our analysis identified
three key species and four key pathways for IBD (Fig. 4).
Key species included Escherichia coli, Oxalobacter formigenes and
Actinomyces graevenitzii. E. coli and O. formigenes have previously




































































































































































































































































































































































































IBD: n = 113 (94%) IBD: n = 1,050 (73%)
300OB: n = 281 (19%)
300OB: n = 4 (3%)
a b
c d
Fig. 3 Differential and cohort-specific microbial co-abundances. a Differential species co-abundances involved in 45 microbial genera. b Differential
pathway co-abundances involved in 41 microbial metabolic categories. Each dot indicates one microbial genus or metabolic category. Each line represents
differential species or pathway co-abundances between species or pathways from either the same or different genera or metabolic categories. The width
and darkness of the lines represent the relative number of differential co-abundances. c Pie chart of 120 cohort-specific species co-abundances showing the
proportion of specific co-abundances detected in each cohort. d Pie chart of 1448 cohort-specific pathway co-abundances showing the proportion of
specific co-abundances detected in each cohort.
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Interestingly, E. coli shows positive co-abundance relationships with
species with pro-inflammatory properties, like Streptococcus mutans,
and negative co-abundance relationships with species with anti-
inflammatory properties, like F. prausnitzii (Supplementary Data 1).
The one key species we identified for IBD, A. graevenitzii, is a
microbe that is most often identified in the oral cavity or respiratory
tract46.
Key IBD pathways included a C1 compound utilization and
assimilation pathway (P23-PWY: reductive tricarboxylic acid
(TCA) cycle I), two vitamin biosynthesis pathways (FOLSYN-
PWY: superpathway of tetrahydrofolate biosynthesis and salvage
and PWY-6612: superpathway of tetrahydrofolate biosynthesis)
and an amino acid biosynthesis pathway (PWY-5505: L-
glutamate and L-glutamine biosynthesis) (Fig. 4b, Supplementary
Data 6). The top key functional pathway in IBD was the reductive
TCA cycle pathway (P23-PWY), which had 76 IBD-specific co-
abundances, and 94.7% of these were replicated in the iHMP-IBD
cohort (Supplementary Data 3 and 6). The reductive TCA cycle is
a carbon dioxide fixation pathway that has been recognized as a
primordial pathway for the production of organic molecules for
the biosynthesis of sugars, lipids, amino acids, pyrimidines and
menaquinone (Fig. 5a)47. For instance, one IBD-specific co-
abundance relationship was related to the biosynthesis of
menaquinone (PWY-5837), which is also known as vitamin K2.
The co-abundance relationship for this pathway in IBD (r= 0.1)
was weaker than in other cohorts (r= 0.3) (Fig. 5b), despite the
higher abundance of this pathway in IBD (FDR < 0.05, Fig. 5c,
Supplementary Data 6). E. coli is known to be an important
species for the biosynthesis of menaquinone, a growth-promoting
factor for a variety of microorganisms in the gut microbiota48. In
line with this, we found that 18.8% of the menaquinone
biosynthesis pathway in IBD patients was contributed by E. coli,
two times higher than in the two population-based cohorts
(Wilcoxon test P < 3.0 × 10−11; Supplementary Data 11). This
finding suggests E. coli as an important contributor to menaquinone
biosynthesis in IBD that may promote the growth of other
microorganisms. Indeed, our study also revealed E. coli as a key
IBD species, exerting IBD-specific co-abundance relationships with
15 species (Supplementary Data 5). Of these, strong positive
correlation was observed for inflammation-related Streptococcus
species, including S. mutans49, Streptococcus vestibularis41 and
Streptococcus infantis42 (Fig. 5d). Accordingly, higher correlations
were observed between menaquinone biosynthesis and Streptococcus
species in IBD than in the other cohorts (Fig. 5e, Supplementary
Data 12).
The microbial co-abundance network in 300OB. Replication of
300OB network in LLD obese individuals: 1107 species and
37,886 pathway co-abundances were detected in the 300OB
cohort (Fig. 2). These estimated co-abundance strengths were
largely replicable in 134 obese individuals with matched age and
body mass index (BMI) from the LLD cohort, with 991 (89.5%)
species co-abundances and 32,963 (87.0%) pathway co-
abundances showing no difference (Cochran-Q test P > 0.05,
Supplementary Fig. 8, Supplementary Data 13 and 14).
Microbial networks in relation to obesity-related diseases: The
300OB cohort was set up to study cardiovascular disease in obese
individuals, including 139 patients with atherosclerotic plaque
and 159 obese controls (Supplementary Table 1). In addition, 35
300OB participants had diabetes. Here we observed only three
species co-abundances related to cardiovascular disease, with all
3 showing stronger co-abundances in patients with plaque than in
patients without (Cochran-Q test FDR < 0.05, Supplementary
Fig. 9, Supplementary Data 13 and 14). These were positive co-
abundances between Dorea longicatena and Dorea formicigener-
ans and negative co-abundances of Lachnospiraceae bacterium
9.1.43BFAA with Coprococcus comes and D. longicatena.
Key pathways in obesity: When we compared microbial co-
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Fig. 4 Cohort-specific species and pathway co-abundances. a Cohort-specific co-abundances identified for three key species in the IBD cohort, involving
33 IBD-specific co-abundances. Each dot indicates one species. Red indicates IBD key species. Each line represents one IBD-specific co-abundance
relationship. b Cohort-specific co-abundances identified for four key pathways in IBD and one key pathway in 300OB, involving 385 cohort-specific co-
abundances. Each line represents a cohort-specific correlation between two pathways. Yellow lines represent obesity-specific co-abundances. Grey lines
represent IBD-specific co-abundances. Each dot indicates one pathway. Pathways belonging to the same metabolic category have the same colour and are
clustered as sub-circles. Colour legends are shown in the plot.
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Fig. 5 Menaquinone biosynthesis related to Streptococcus overgrowth in IBD. a Menaquinone biosynthesis (PWY-5837) from the reductive TCA cycle
(P23-PWY) in bacteria. b The menaquinone biosynthesis pathway shows IBD-specific interaction with the reductive TCA cycle pathway. c Both
menaquinone biosynthesis and reductive TCA cycle pathway abundance are significantly higher (ANOVA test, FDR < 0.05) in the IBD cohort than in the
two population-based cohorts. Box plots show medians and the first and third quartiles (the 25th and 75th percentiles) of abundance after correcting for
age and sex, respectively. The upper and lower whiskers extend the largest and smallest value no further than 1.5 × IQR, respectively. Outliers are plotted
individually. (Source data is provided as a Source data file). d Three Streptococcus species show IBD-specific co-abundance with Escherichia coli. e The
menaquinone biosynthesis pathway shows strong positive correlation with three Streptococcus species in IBD. N= 2379 independent samples are involved
(NLLD= 1135, N500FG= 450, N300OB= 298, NIBD= 496). The forest plots show co-abundance strength and direction in each cohort, with square dot for the
correlation coefficient and bar for the 95% confidence interval.
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pathway co-abundances that showed a significantly different
effect, i.e. obesity-specific co-abundances. One key pathway in
obesity was degradation of allantoin (PWY0-41, Fig. 4b, Supple-
mentary Data 6), which showed obesity-specific co-abundance
relationships with 85 pathways. Allantoin is one of the active
principles in various plants, e.g. yams, and is found to enhance
insulin secretion and lower plasma glucose43,44. Its degradation
product, oxamate, plays an inhibitory role in oxaloacetate/
aspartate amino acids45. In line with this, we found that the
allantoin degradation pathway showed stronger negative correla-
tions with the biosynthesis pathways of oxaloacetate/aspartate
amino acids (including lysine, homoserine, methionine, threonine
and isoleucine) and the biosynthesis pathway of aspartate
(PWY0-781, Fig. 6), which were both positively associated with
fasting glucose level and negatively associated with fasting insulin
level (P < 0.05, Supplementary Table 2).
Discussion
This study is a microbial co-abundance network analysis based on
metagenomics data, involving 2379 participants from two
population-based cohorts (LLD and 500FG) and two disease
cohorts (IBD and 300OB). We report 3454 species and 43,355
pathway co-abundance relationships that were significant in at
least one cohort. Among them, the effect sizes of 38.6% of species
co-abundances and 64.3% of pathway co-abundances were sig-
nificantly different between cohorts. In particular, 113 species co-
abundances and 1050 pathway co-abundances showed IBD
cohort-specific effects and 281 pathway co-abundances had spe-
cific effects in the 300OB cohort. Our study provides evidence
that microbial dysbiosis can be reflected in alterations in micro-
bial co-abundance.
Our study yielded several findings. We identified three species
and four pathways in IBD and one pathway in 300OB that served
as key players in disease-specific co-abundance networks. Key
IBD-associated species included E. coli and O. formigenes14,50,51.
A higher abundance of the pathogenic species E. coli has pre-
viously been associated with IBD50,51, likely due to an increased
release of oxidized haemoglobin into the intestinal lumen as a
result of chronic inflammation of the gastrointestinal walls52,53.
Consistent with this, we replicated high abundances of E. coli and
low abundances of anaerobic metabolism pathways in IBD. E. coli
also showed strong positive co-abundance with other
inflammation-inducing species in IBD, including streptococcus
species such as S. mutans49, S. vestibularis41 and S. infantis42. In
contrast, these co-abundances were either weak or negative in our
population-based and obesity cohorts. We further identified A.
graevenitzii as a key species in IBD. Although no evidence sup-
ports a direct role for Actinomyces in the pathogenesis of IBD, A.
graevenitzii has been associated with coeliac disease in children54
and can induce actinomycosis55,56, with both conditions sharing
similar abdominal pathologies with IBD57. Two case reports have
also suggested that Actinomyces may aggravate the intestinal
injuries caused by inflammation58,59.
The top key functional pathway in IBD was the reductive TCA
cycle pathway (P23-PWY), which had 76 IBD-specific co-abun-
dances. Interestingly, the key IBD species E. coli is known to be an
important species for the biosynthesis of menaquinone, a growth-
promoting factor for a variety of microorganisms in the gut
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Fig. 6 Allantoin degradation pathway links to glycaemia in obesity. The allantoin degradation pathway shows stronger negative correlation with 14 amino
acid biosynthesis pathways in the obesity cohort compared to the other cohorts. These pathways represent the biosynthesis of six amino acids: a
isoleucine (PWY-5103, PWY-3001, BRANCHED-CHAIN-AA-SYN-PWY and ILEUSYN-PWY), b methionine (PWY-6151, PWY-5347, MET-SAM-PWY and
HOMOSER-METSYN-PWY), c threonine (THRESYN-PWY and PWY-724), d lysine (PWY-5097 and PWY-2942), e aspartate (PWY0-781) and f
homoserine (METSYN-PWY). All six amino acids are involved in the oxaloacetate/aspartate amino acids biosynthesis pathway. Lines with arrows
represent metabolic relationships. Lines with a circle represent an inhibitory role in a metabolic pathway. N= 2379 independent samples are involved
(NLLD= 1135, N500FG= 450, N300OB= 298, NIBD= 496). The forest plots show co-abundance strength and direction in each cohort, with square dot for the
correlation coefficient and bar for the 95% confidence interval.
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microbiota48. In line with this, we found that 18.8% of the
menaquinone biosynthesis pathway in IBD patients was attrib-
uted to E. coli, which is two times higher than in the two
population-based cohorts (Wilcoxon test P < 3.0×10−11). Another
notable IBD key pathway is the tetrahydrofolate pathway, which
is responsible for folic acid derivative biosynthesis and supple-
mentation of folic acid. This pathway has been shown to reduce
the risk of colorectal cancer in IBD patients60. Interestingly,
previous research has shown that oral intake of L-glutamine
attenuates the colitis induced by dextran sulfate sodium in mice61.
We identified a negative co-abundance with L-glutamine bio-
synthesis and biosynthesis of other amino acids like L-isoleucine
and L-methionine. Previous research showed that both these
amino acids play an important role in the immune system62,63. L-
glutamine has been tested as supplement in patients with IBD but
did not show improvements in clinical outcomes like disease
activity scores64. Our results show large numbers of connections
for L-glutamine with other pathways such as the biosynthesis of
other amino acids. These pathways might also be of interest when
exploring L-glutamine as an intervention for IBD.
In obesity, we identified the allantoin degradation pathway as a
key pathway, showing obesity-specific co-abundance relationship
to 85 pathways, mainly negative correlations with biosynthesis of
oxaloacetate/aspartate amino acids. These pathways are related to
insulin secretion and glucose metabolism. However, their co-
abundance relationships did not show significant differences
between patients and non-diabetic individuals, which is likely due
to a power issue as there were only 35 diabetic patients in 300OB.
Instead, we found three species co-abundances related to presence
of atheriosclerotic plaque, involving D. longicatena, D. for-
micigenerans, L. bacterium 9.1.43BFAA and C. comes. Notably, D.
Longticatena and Lachnospiraceae species have been linked to
atherosclerotic cardiovascular disease9.
Altogether, our analyses show that microbial dysbiosis in disease
may not be driven solely by differences in abundance level, it may
also reflect shifts in microbial interactions that are mirrored in co-
abundance analyses. Particularly when applied to metagenomics
sequence data, pathway-based co-abundance networks provide
further insights into functional dysbiosis in IBD and obesity.
However, we also acknowledge several limitations of our study. This
is an in silico network analysis based on correlation in bacterial
abundance levels. Even with the large sample size, our study is still
undersized for making comparisons to the number of interactions
assessed. In recent years, many different network tools have been
developed to tackle the statistical challenges in inferring networks
for compositional data. In this study, we applied two independent
methods, SparCC and SpiecEasi, to establish microbial co-
abundance networks based on MetaPhlan and HUMAnN2 anno-
tation. Our analysis can thus be biased due to these annotation
tools. Other annotation tools, e.g. mcSEED65, may yield different
pictures of microbial community and functional profile, thereby
identifying different co-abundance networks. Thus such in silico-
based network inferences require further functional validation.
Although bacterial genes are believed to be expressed uniformly66,
previous studies have also shown that meta-transcription can exert
dynamic changes in response to environmental perturbations that
cannot be detected at the metagenome level67,68. Thus, in order to
understand the microbial ecosystem in terms of functional inter-
action in diseases, we need complementary approaches like meta-
proteomics and meta-metabolomics that provide a more direct
readout of the functional properties of the gut microbiome. Fur-
thermore, the cross-sectional design of this study makes it hard to
assess the stability of our findings over time. However, we did
observe similar findings for the iHMP-IBD cohort for 98.2% of
species co-abundances and 99.4% of pathway co-abundances
between two time points spanning 1 year (Cochran-Q test P > 0.05).
This implies that co-abundance relationships are largely consistent
over time.
In addition, due to our study design, we cannot disentangle
cause from consequence. Longitudinal studies are therefore
warranted and should be combined with functional validation.
Moreover, especially in the context of IBD, which is a hetero-
geneous disease, we had limited ability to pinpoint co-abundance
networks to specific disease characteristics like the subtypes CD
and UC. This is probably due to the lack of power to detect
this by subgrouping our cohorts. Larger cohorts with well-
documented disease characteristics are needed in the future.
This study presents the microbial network analysis to examine
both microbial species and functional pathways based on meta-
genomics sequencing. Our data show that dysbiosis of the gut
microbial ecosystem in disease can not only be assessed by the
altered abundance level but can also be seen at the level of
microbial interaction, at least in terms of co-abundances. We
have also identified IBD- and obesity-specific species and path-
ways that potentially play important roles in regulating the
microbial ecosystem in disease, and these disease-specific
microbial interactions extend our current knowledge about the
role of the microbiome in disease.
Methods
Study cohorts. All four cohorts used in this study have been described
before3,14,69,70. In short, the LLD cohort is a large prospective cohort study from
the north of the Netherlands71. LLD contains 58.20% females and 41.80% males,
the mean age (SD) of participants is 45.04 (13.60) years and their mean BMI is
25.26 (4.18) (Supplementary Fig. 1). In this study, we included 1135 LLD indivi-
duals for whom there is metagenomics and phenotype data3.
The 500FG cohort consists of 534 healthy adult volunteers from the
Netherlands69,70. In 500FG, 56.50% are women and 43.50% are men, the mean age
of participants is 27.43 (12.35) years and their mean BMI is 22.70 (2.72)
(Supplementary Fig. 1). In this study, we included 450 500FG participants for
whom metagenomics data are available.
The 300OB is a part of the Functional Genomics project and consists of 302
individuals from the Netherlands with a BMI >2770,72,73. These individuals have
been clinically screened for obesity-related comorbidities. Around half of
participants are clinically diagnosed with metabolic syndrome. 300OB is 55.70%
male and 44.30% female, the mean age of participants is 67.07 (5.39) years and
their mean BMI is 30.73 (3.48) (Supplementary Fig. 1). In this study, we included
298 participants from 300OB for whom metagenomics data are available.
The 1000 Inflammatory Bowel Disease (1000IBD) cohort consists of patients with
IBD recruited at the specialized IBD outpatient clinic of the University Medical
Center Groningen in the Netherlands14,74. IBD diagnosis was made based on
accepted radiological, endoscopic and histopathological evaluation. The 1000IBD
cohort is 60.70% female and 39.30% male, the mean age of participants is 43.45
(14.52) years and their mean BMI is 25.55 (5.17) (Supplementary Fig. 1). In this study,
we included 496 IBD participants for whom metagenomics data are available.
Ethical approval. All participants signed an informed consent form prior to
sample collection. Institutional ethics review board (IRB) approval was available for
all four cohorts: the LLD (ref. M12.113965) and the IBD (IRB-number 2008.338)
cohorts were approved by the UMCG IRB and the 500FG study (NL42561.091.12,
2012/550) and 300OB (NL46846.091.13) cohorts were approved by the Ethical
Committee of Radboud University Nijmegen.
Metagenomic data generation and pre-processing. All participants from the
four cohorts were asked to collect faecal samples at home and to place them in their
home freezer (−20 °C) within 15 min after production. Subsequently, a nurse
visited the participant to pick up the faecal samples on dry ice and transfer them to
the laboratory. Aliquots were then made and stored at −80 °C until further pro-
cessing. The same protocol for faecal DNA isolation and metagenomics sequencing
was used for all four cohorts. Faecal DNA isolation was performed using the
AllPrep DNA/RNA Mini Kit (Qiagen, cat. 80204). After DNA extraction, faecal
DNA was sent to the Broad Institute of Harvard and MIT in Cambridge, MA, USA,
where library preparation and whole-genome shotgun sequencing were performed
on the Illumina HiSeq platform. From the raw metagenomic sequencing data, low-
quality reads were discarded by the sequencing facility and reads belonging to the
human genome were removed by mapping the data to the human reference gen-
ome (version NCBI37) with Bowtie2 (v2.1.0)75.
The relative abundance of gut microbial taxonomic units was determined using
MetaPhlan (v2.7.2)76, and the relative abundances of metabolic pathways were
determined using the HUMAnN2 pipeline (v0.10.0)77, which maps DNA/RNA
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reads to a customized database of functionally annotated pan-genomes.
HUMAnN2 reported the abundances of gene families from the UniProt Reference
Clusters78 (UniRef90), which were further mapped to microbial pathways from the
MetaCyc metabolic pathway database79,80. In total, we detected 698 species and 489
pathways present in at least 1 of the 4 cohorts. To deal with sparse microbial data
in the network analysis, we focused on species/pathways present in at least 20% of
samples in at least one cohort. This provided a confined list of 134 species and 343
pathways for use in the network analysis. Together these accounted for, on average,
86.9% and 99.9% of taxonomic and functional compositions, respectively.
Statistical analysis. Co-abundance network inference: co-abundance analysis on
compositional data is challenging because it is likely to exhibit spurious correla-
tions due to the dependency of fractions (i.e. relative abundance sums to 1)29,81–84.
In particular, the problem can be more serious in a microbial community with low
compositionality85. We therefore first assessed the inverse Simpson index of
microbial composition for the effective number of species (neff). Our analysis
showed high compositionality in both functional pathway composition (2.09, 2.10,
2.11 and 2.08 in LLD, 500FG, 300OB and IBD, respectively) and species compo-
sition (10.74, 11.87, 12.30 and 8.80 in LLD, 500FG, 300OB and IBD, respectively).
Following the suggestion of Weiss et al.85, based on their assessment of the per-
formance of eight different methods (Bray–Curtis, Pearson, Spearman, CoNet,
LSA, MIC, RMT and SparCC), we decided to use the SparCC method because it
has been proven to be able to infer linear relationships with high precision for high
diversity compositions with neff < 13. Species composition data from MetaPhlan
was converted to predicted read counts by multiplying relative abundances by the
total sequence counts and then subjected to a Python-based SparCC tool29. For
pathway analysis, the read counts from HUMAnN2 were directly used for SparCC.
Significant co-abundance was controlled at FDR 0.05 level using 100× permutation.
In each permutation, the abundance of each microbial factor was randomly
shuffled across samples. To reduce indirect associations, we further applied Spie-
cEasi (v1.0.6), which infers the microbial network underlying graphical model
using the concept of conditional independence38. In this way, we obtained
3454 species and 43,355 pathway co-abundances that were detectable by both
methods (Fig. 1).
Co-occurrence network inference: presence and absence of each bacterial
species and metabolic pathway were treated as binary traits. The pair-wise co-
occurrence relationship between two microbial factors (species or pathway) in each
cohort was assessed using Pearson’s chi-squared test. If the number of co-
occurrence pairs was greater than the number of co-exclusion pairs, the two
microbial factors were considered to be a co-occurrence. If the number of co-
occurrence pairs was less than the number co-exclusion pairs, the two factors were
considered to be a co-exclusion. Permutation (100×) was conducted to determine
significance at an FDR < 0.05. In each permutation, the presence and absence of
each microbial factor was randomly shuffled across samples. At the species level,
we detected 6015 co-occurrence relationships that were found in at least one
cohort, with 3423 found in LLD, 1845 in 500FG, 1199 in 300OB and 4701 in IBD
(Supplementary Data 2). At the pathway level, we detected 19,903 co-occurrence
relationships that appeared in at least one cohort, with 13,501 found in LLD, 7581
in 500FG, 7580 in 300OB and 16,596 in IBD (Supplementary Data 4).
Network heterogeneity analysis: To assess the variability of networks among the
four cohorts, we conducted Cochran-Q tests to assess the heterogeneity of effect
sizes and directions across the four cohorts for each co-abundance (correlation
coefficient generated by SparCC) and co-occurrence (odds ratio). Here we treated
each cohort as one study and conducted the Cochran-Q test using the metagen()
function from the package meta (v4.9.5) in R, which calculates the squared
difference between individual study effects and the pooled effect using inverse
variance weighting86. For each co-abundance, the P values from the Cochran-Q test
were recorded, and co-abundances with significant heterogeneity were controlled at
the FDR 0.05 level determined by permutation (100×). In this case, all samples
from the four cohorts were randomly shuffled across cohorts, i.e. shuffling the
cohort labels but keeping the correlation structure of species and pathways intact.
Co-abundances with a Cochran-Q test FDR < 0.05 were considered heterogeneous,
while co-abundances with Cochran-Q test P > 0.05 were considered stable. We also
summarized species co-abundance co-abundances based on microbial genus and
pathway co-abundance co-abundances based on metabolic category.
Cohort-specific co-abundance selection. For heterogeneous co-abundances and
co-occurrences (Cochran-Q test FDR < 0.05), we further assessed whether these
relationships showed cohort specificity, i.e. whether the effect size of co-abundance/
co-occurrence in one cohort was very different from that in the other three. In this
analysis, effect size for co-abundance was the SparCC correlation coefficient and
the odds ratio for co-occurrence. We adopted interquartile ranges (IQRs) based the
outlier detection method (Supplementary Fig. 10)87. We ranked the effect sizes
from low to high, say b1, b2, b3, b4, and then calculated the corresponding 25%,
50% and 75% quartile values (Q1, Q2 and Q3, respectively). IQR was then cal-
culated, and we assessed whether the smallest or largest effect size fell outside of
Q1− 2 × IQR or Q3+ 2 × IQR. If only one met the condition, we called this co-
abundance specific and assigned it to the corresponding cohort (Supplementary
Fig. 10). To assess whether cohort-specific co-abundances were enriched for a
specific cohort, we conducted Fisher’s exact test. We also calculated the average
FDR of cohort-specific co-abundances using 100× permutations as described above
for the heterogeneity analysis.
Key microbial species and pathway detection. To assess to what extent cohort-
specific microbial relationships were linked to a specific species or pathway, we
calculated the number of cohort-specific microbial relationships per species/
pathway. To define the key species/pathway, we took the maximum number of
false cohort-specific relationships per species/pathway from each permutation and
determined the key species/pathway cut-off as the upper range of the 95% of
confidence interval based on 100× permutations. At this cut-off, there is a 5%
probability that a false enrichment could occur by chance. In this way, a species
with at least 13 cohort-specific co-abundances or a pathway with at least 70 cohort-
specific co-abundances was recognized as a key species or pathway. For co-
occurrence networks, these numbers were 10 for key species and 45 for key
pathways. In such a way, we detected 192 cohort-specific species co-abundances
and 2235 cohort-specific pathway co-abundances.
Assessing impact of confounding factors. The age and sex distributions were
different between cohorts (Supplementary Fig. 1). To assess the impact of age and
sex, we conducted partial correlation analysis (Supplementary Fig. 11). For
example, to assess the co-abundance between species A and B, we first assessed the
Pearson correlation of A and B to each covariant, say C, respectively. Then, a
pairwise correlation matrix of A, B and C was subjected to partial correlation
(Supplementary Fig. 11) using the partial correlation function cor2pcor from the R
package corpcor (version 1.6.9). This insured that the partial correlation deter-
mined between A and B was independent of the covariant C. To assess the impact,
we compared the correlation coefficient between SparCC correlation and partial
correlation for all co-abundances and found comparable effect size (Supplementary
Fig. 12). After regressing out the confounding effects of age and sex on cohort-
specific co-abundances, 120 out of 192 (62.5%) species and 1448 out of 2235
(64.8%) pathway co-abundances remained cohort specific.
Replication of microbial networks. To replicate microbial networks in IBD, we
used data from 77 IBD patients from the iHMP-IBD as a replication cohort88.
Given the iHMP-IBD’s longitudinal study design, we could examine metagenomics
data from the first and the last sample collection for each individual. In all, 91% of
the species (123 out of 134) and 99% of the pathways (340 out of 343) found in our
IBD cohort were also detected in the first sample collection in iHMP-IBD. The
differences in co-abundance strength between the IBD cohort and the iHMP-IBD
cohort were assessed using Cochran-Q test. A significant P > 0.05 was applied to
define replicable co-abundances. We also investigated the stability of microbial
networks in iHMP-IBD by comparing the microbial co-abundances in the first and
last sample collection from the same participants using the same approach.
To replicate microbial networks in 300OB, we selected 134 obese individuals
from the LLD cohort with matched age and BMI. Here we considered a co-
abundance to be replicable if the Cochran-Q test heterogeneity between the
discovery and replication cohorts was not significant at P > 0.05.
Assessing the relevance of microbial co-abundances to sub-phenotypes.
Patients in the IBD and 300OB cohorts have different disease subtypes, and both
cohorts had higher proportions of drug users than our population cohorts. In
particular, the IBD cohort contained 276 patients with CD and 189 with UC.
Within the IBD cohort, 126 patients took PPIs and 97 took antibiotics. In the
300OB cohort, 53.4% (159 out of 298) had an atherosclerotic plaque detected by
ultrasound72 and 35 were diabetic. To assess the co-abundance related to disease
sub-phenotypes, we split the cohorts based on disease subtypes or medication use
and inferred microbial co-abundance using SparCC. Cochran-Q test was applied to
assess the differential microbial co-abundances at FDR < 0.05.
Species contributions to pathways and species–pathway associations. Since
the pathway abundances reported by HUMAnN2 are computed at both commu-
nity and individual species level77, we further looked into the contribution of
species to each pathway and reported the top contributor (species). To show the
functional relationship between species and pathways (e.g. whether a given path-
way has the potential to promote the growth of a species through its metabolic
products), we also checked the correlation (Spearman) between microbial species
and pathway abundance after adjusting for age, sex and read depth using a linear
regression model89. FDR was further calculated based on 100× permutation.
Network visualization. Cohort-specific networks based on cohort-specific co-
abundances were visualized using a circle plot or heatmap with hierarchical clus-
tering analysis (ward.D clustering based on Minkowski distance). Both species and
pathways networks were visualized using the package igraph (v1.2.4.1)90 in R. For
species networks, species belonging to the same genus were clustered together. For
pathway networks, pathways from the same metabolic category were presented in a
sub-circle, and categories with a limited number of pathways (<4) were grouped
into the other category. Classification of pathways was based on the MetaCyc
metabolic pathway database79,80.
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Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
All relevant data supporting the key findings of this study are available within the article
and its Supplementary Information files. Data underlying Fig. 5c and Supplementary
Fig. 2 are provided as a Source data file. Data underlying all the other figures are provided
in Supplementary Data and data repositories: LifeLines-Deep cohort [https://www.ebi.ac.
uk/ega/datasets/EGAD00001001991], 1000 IBD cohort [https://www.ebi.ac.uk/ega/
datasets/EGAD00001004194], 300OB cohort [https://ega-archive.org/dacs/
EGAC00001001143], and 500FG cohort [https://www.ncbi.nlm.nih.gov/bioproject/?
term=PRJNA319574]. The iHMP data are available via https://ibdmdb.org/tunnel/
public/summary.html. Due to informed consent regulation, the data sets of the Lifelines-
DEEP, IBD, 300OB and 500FG cohorts are available upon request to the University
Medical Center of Groningen (UMCG), Lifelines and Radboud University Medical
Center, respectively. This includes the submission of a letter of intention to the
corresponding data access committee [the Lifelines Data Access Committee for the
LifeLines-DEEP data (Jackie Dekens, e-mail: j.a.m.dekens@umcg.nl), 1000 IBD Data
access Committee UMCG for the IBD data (Melinde E. Wijers, e-mail: m.e.wijers@umcg.
nl) and the Human Functional Genomics Data Access Committee for 500FG and 300OB
data (Martin Jaeger, e-mail: Martin.Jaeger@radboudumc.nl)]. Data sets can be made
available under a data transfer agreement and the data usage access is subject to local
rules and regulations. Source data are provided with this paper.
Code availability
For this study, the following software was used: kneadData (v0.4.6.1), Bowtie2 (v2.1.0),
MetaPhlAn2 (v2.7.2), HUMAnN2 (v0.10.0), SparCC Python package, R (v3.5.2),
SpiecEasi R package (v1.0.6), and meta R package (v4.9.5). Code used for generating the
microbial abundance profiles is publicly available at https://github.com/GRONINGEN-
MICROBIOME-CENTRE/Groningen-Microbiome/blob/master/Scripts/
Metagenomics_pipeline_v1.md. Code used for the statistical analyses is publicly available
at https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-
Microbiome/tree/master/Projects/Microbial%20co-abundance%20network. Source data
are provided with this paper.
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